Notes to the Consolidated Financial Statements for the Year Ended 30 June 2014 NOTE 14: TRADE AND OTHER PAYABLES  NOTE 16: CONTRIBUTED EQUITY (a) Ordinary Shares, reported in post consolidation share numbers for 2014 and 2013  (b) Share options At the end of the financial year, there were 23,320,173 unissued ordinary shares (2013: 17,594,313) over which options were outstanding. Benitec Biopharma Ltd  Annual Report 2014 Page 33 114,898,992 (2013: 46,076,562) issued and fully paid ordinary shares  The share capital of the Company consists only of fully paid ordinary shares; the shares do not have a par value. All shares are equally eligible  to receive dividends and the repayment of capital and represent one vote at the shareholders’ meeting of the Company. The Board monitors  capital funding requirements in its competitive landscape and continues to actively manage its cash requirements as part of a broader capital  management program to ensure adequate capital is in place to fund the company’s operations.  2014 2013 $ $ CURRENT Unsecured liabilities Trade creditors  572,557  279,994 Sundry creditors and accrued expenses  215,612  374,560 Deferred consideration - Tacere vendors  -  357,179 788,169 1,011,733 CURRENT Provision for employee benefits  166,511  98,637 NOTE 15: PROVISIONS Contributed Equity at the beginning of the reporting period, (after applying the 25:1 consolidation)  89,609,248  87,348,819 Placements in March to June 2013  -  1,262,000 Placement in July 2013 7,618,326 - Share Purchase Plan August 2013  2,820,000 - Issued to Tacere shareholders on purchase of Tacere  -  1,173,585 Tacere escrow shares released October 2013  357,190 - Options exercised during the year  185,503 - Placements in February and April 2014 31,496,504 - Transaction costs relating to share issues during the year  (2,901,095)   (175,156) Contributed Equity at the close of the reporting period  129,185,676  89,609,248 Number Number At the beginning of reporting period 46,076,562  38,825,141 Shares issued during the year  68,822,430  7,251,421 114,898,992 46,076,562 Details  Expiry Date  Exercise Price  Number Strategic Advisor warrants  4 August 2014  22.500  245,078  ESOP Options  19 August 2014  0.510  260,000  NED Options  19 August 2014  0.570  120,000  Unlisted Options - placement  18 February 2015  0.325  662,767  Unlisted other options  10 April 2015  2.500  480,000 